Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
about
Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data.Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives.Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target[Hypertension update 2016].Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
P2860
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@ast
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@en
type
label
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@ast
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@en
prefLabel
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@ast
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@en
P2093
P2860
P356
P1476
Risk of hyperkalemia and combi ...... n- and insurance-based cohort.
@en
P2093
Ingrid Schubert
Peter Ihle
Sascha Abbas
Sebastian Harder
P2860
P304
P356
10.1002/PDS.3748
P577
2015-02-12T00:00:00Z